Detail akcie Oxford Biomedica Rg online

Business Summary: Oxford Biomedica PLC is a contract development and manufacturing organization (CDMO) in cell and gene therapy. The Company is engaged in providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV), adenovirus and other viral vector types. It offers a number of technologies for viral vector manufacturing, including a fourth-generation lentiviral vector system (the TetraVecta system), a dual-plasmid system for AAV production, suspension and perfusion process using process enhancers and stable producer and packaging cell lines. Its LentiVector platform technology is an advanced lentiviral vector-based gene delivery system which is designed to overcome the safety and delivery problems associated with earlier generations of vector systems. Its AAV platform, which offers a proprietary plug and play dual-plasmid system for transient transfection, as well as a standard triple transfection system for AAV-based gene therapies.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2024, Oxford BioMedica plc revenues increased 44% to L128.8M. Net loss decreased 73% to L43.2M. Revenues reflect Europe segment increase from L19.8M to L41.9M, United States of America segment increase of 22% to L80M. Lower net loss reflects Innovation costs decrease of 92% to L4.5M (expense), Other Operating Income/Expenses increase of 87% to L5.3M (income).